Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor

NEW YORK, NY – November 21, 2017 – New data published in the current issue of the peer-reviewed scientific journal Neurotoxicity Research[1] confirm that sigma-1 agonists, including multiple investigational compounds from Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL), induce an anti-oxidant effect and protect mitochondrial function in pathological central nervous system conditions. In…